Jill Hacker has over 20 years of direct data management experience in the Biotechnology/Pharmaceutical Industry. She has worked on many Solid Tumor and Blood Related Cancer Clinical Trials over her career. She was part of the Rituxan and Zevalin approvals at IDEC Pharmaceuticals for Non-Hodgkin’s Lymphoma. Her biggest achievement to date has been in the Cell Therapy space where she was one of two data managers vital in obtaining accelerated approval for Yescarta in the United States and Europe. Yescarta is the first CAR T therapy approved for adults living with large B-cell Lymphoma. Jill earned her RN/BSN from Johns Hopkins School of Nursing and also has a Bachelor’s Degree from The University of Pennsylvania in The History and Sociology of Science.